Skip to main content

Biosimilars are back.... Or are they?

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American



On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


As blockbuster drugs go off patent, the pharmaceutical industry is scrambling for fresh revenue sources. Follow-on versions of biologics, or “biosimilars,” are being pitched as BigPharma’s saving grace. One question remains unaddressed in the discussion: is anyone actually planning on selling biosimilars in the United States? What are biosimilars? Biosimilars are a new class of [...]

About Khadijah Britton

Khadijah M. Britton, JD, is founder of BetterBio, a Massachusetts-registered nonprofit and fiscally sponsored project of the 501(c)(3) Fractured Atlas whose mission is to empower journalism that reinforces the intimate connection between life and science. BetterBio provides a platform for comprehensive science reporting, challenging us to ask hard questions and debunk dangerous myths while addressing our collective social responsibility. Khadijah also serves as Chief Communications Officer for the Open Science Alliance and 2011 Open Science Summit. She has recently relocated to Washington, DC and is excited to be at the heart of US health and science policy.

More by Khadijah Britton